Novartis N Stock Net Income
| NOT Stock | 139.50 1.45 1.05% |
As of the 23rd of February, NOVARTIS N secures the Market Risk Adjusted Performance of 0.9596, mean deviation of 0.9174, and Risk Adjusted Performance of 0.195. Concerning fundamental indicators, the technical analysis model lets you check available technical drivers of NOVARTIS N, as well as the relationship between them.
NOVARTIS N Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 14 B | 11.3 B | |
| Net Income Applicable To Common Shares | 6.9 B | 8.5 B | |
| Net Income | 14 B | 13.4 B |
NOVARTIS | Net Income |
The evolution of Net Income for NOVARTIS N provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NOVARTIS N compares to historical norms and industry peers.
Latest NOVARTIS N's Net Income Growth Pattern
Below is the plot of the Net Income of NOVARTIS N over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in NOVARTIS N financial statement analysis. It represents the amount of money remaining after all of NOVARTIS N operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is NOVARTIS N's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NOVARTIS N's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 13.98 B | 10 Years Trend |
|
Net Income |
| Timeline |
NOVARTIS Net Income Regression Statistics
| Arithmetic Mean | 11,814,702,941 | |
| Geometric Mean | 11,191,806,808 | |
| Coefficient Of Variation | 36.36 | |
| Mean Deviation | 3,049,768,166 | |
| Median | 10,210,000,000 | |
| Standard Deviation | 4,295,797,593 | |
| Sample Variance | 18453877T | |
| Range | 17.3B | |
| R-Value | 0.28 | |
| Mean Square Error | 18106689.9T | |
| R-Squared | 0.08 | |
| Significance | 0.27 | |
| Slope | 240,820,098 | |
| Total Sum of Squares | 295262031.4T |
NOVARTIS Net Income History
NOVARTIS N 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NOVARTIS N's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NOVARTIS N.
| 11/25/2025 |
| 02/23/2026 |
If you would invest 0.00 in NOVARTIS N on November 25, 2025 and sell it all today you would earn a total of 0.00 from holding NOVARTIS N or generate 0.0% return on investment in NOVARTIS N over 90 days. NOVARTIS N is related to or competes with DANAHER (DAPSG), Advanced Micro, Philip Morris, Amgen, and Hong Kong. NOVARTIS N is entity of Germany. It is traded as Stock on STU exchange. More
NOVARTIS N Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NOVARTIS N's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NOVARTIS N upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.04 | |||
| Information Ratio | 0.1865 | |||
| Maximum Drawdown | 5.41 | |||
| Value At Risk | (1.41) | |||
| Potential Upside | 2.7 |
NOVARTIS N Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NOVARTIS N's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NOVARTIS N's standard deviation. In reality, there are many statistical measures that can use NOVARTIS N historical prices to predict the future NOVARTIS N's volatility.| Risk Adjusted Performance | 0.195 | |||
| Jensen Alpha | 0.2723 | |||
| Total Risk Alpha | 0.1919 | |||
| Sortino Ratio | 0.2187 | |||
| Treynor Ratio | 0.9496 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NOVARTIS N's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NOVARTIS N February 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.195 | |||
| Market Risk Adjusted Performance | 0.9596 | |||
| Mean Deviation | 0.9174 | |||
| Semi Deviation | 0.7138 | |||
| Downside Deviation | 1.04 | |||
| Coefficient Of Variation | 405.9 | |||
| Standard Deviation | 1.23 | |||
| Variance | 1.5 | |||
| Information Ratio | 0.1865 | |||
| Jensen Alpha | 0.2723 | |||
| Total Risk Alpha | 0.1919 | |||
| Sortino Ratio | 0.2187 | |||
| Treynor Ratio | 0.9496 | |||
| Maximum Drawdown | 5.41 | |||
| Value At Risk | (1.41) | |||
| Potential Upside | 2.7 | |||
| Downside Variance | 1.09 | |||
| Semi Variance | 0.5095 | |||
| Expected Short fall | (1.07) | |||
| Skewness | 0.2848 | |||
| Kurtosis | 0.88 |
NOVARTIS N Backtested Returns
NOVARTIS N appears to be very steady, given 3 months investment horizon. NOVARTIS N has Sharpe Ratio of 0.33, which conveys that the firm had a 0.33 % return per unit of standard deviation over the last 3 months. We have found thirty technical indicators for NOVARTIS N, which you can use to evaluate the volatility of the firm. Please exercise NOVARTIS N's Market Risk Adjusted Performance of 0.9596, risk adjusted performance of 0.195, and Mean Deviation of 0.9174 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, NOVARTIS N holds a performance score of 26. The company secures a Beta (Market Risk) of 0.31, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NOVARTIS N's returns are expected to increase less than the market. However, during the bear market, the loss of holding NOVARTIS N is expected to be smaller as well. Please check NOVARTIS N's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether NOVARTIS N's current price movements will revert.
Auto-correlation | 0.93 |
Excellent predictability
NOVARTIS N has excellent predictability. Overlapping area represents the amount of predictability between NOVARTIS N time series from 25th of November 2025 to 9th of January 2026 and 9th of January 2026 to 23rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NOVARTIS N price movement. The serial correlation of 0.93 indicates that approximately 93.0% of current NOVARTIS N price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.93 | |
| Spearman Rank Test | 0.9 | |
| Residual Average | 0.0 | |
| Price Variance | 33.83 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
NOVARTIS Operating Income
Operating Income |
|
Based on the recorded statements, NOVARTIS N reported net income of 13.98 B. This is much higher than that of the Metals & Mining sector and significantly higher than that of the Materials industry. The net income for all Germany stocks is notably lower than that of the firm.
NOVARTIS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NOVARTIS N's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NOVARTIS N could also be used in its relative valuation, which is a method of valuing NOVARTIS N by comparing valuation metrics of similar companies.NOVARTIS N is currently under evaluation in net income category among its peers.
NOVARTIS N ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NOVARTIS N's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NOVARTIS N's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
NOVARTIS Fundamentals
| Current Valuation | 239.79 B | ||||
| Price To Book | 6.09 X | ||||
| Price To Sales | 4.77 X | ||||
| Revenue | 56.67 B | ||||
| Gross Profit | 33.18 B | ||||
| Net Income | 13.98 B | ||||
| Total Debt | 5.52 B | ||||
| Cash Flow From Operations | 19.14 B | ||||
| Price To Earnings To Growth | 1.38 X | ||||
| Market Capitalization | 160.08 B | ||||
| Total Asset | 110.95 B | ||||
| Retained Earnings | 46.56 B | ||||
| Working Capital | 3.18 B | ||||
| Annual Yield | 0.05 % | ||||
| Net Asset | 110.95 B |
About NOVARTIS N Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NOVARTIS N's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NOVARTIS N using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NOVARTIS N based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NOVARTIS Stock Analysis
When running NOVARTIS N's price analysis, check to measure NOVARTIS N's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NOVARTIS N is operating at the current time. Most of NOVARTIS N's value examination focuses on studying past and present price action to predict the probability of NOVARTIS N's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NOVARTIS N's price. Additionally, you may evaluate how the addition of NOVARTIS N to your portfolios can decrease your overall portfolio volatility.